Minerva Neurosciences (NERV) Interest Coverage Ratio (2014)
Minerva Neurosciences' (NERV) quarterly Interest Coverage Ratio came in at 1.02 in Q1 2026, up 73.88% on a QoQ basis from 3.92 in Q4 2025.
Analysis
Minerva Neurosciences (NERV) Interest Coverage Ratio (2014) Analysis & Trends
Minerva Neurosciences (NERV) has 14 years of Interest Coverage Ratio data on file, last reported at 1.02 in Q1 2026.
- Quarterly Interest Coverage Ratio changed N/A year-over-year to 1.02 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.71 (changed N/A YoY) and the FY2025 annual result came in at 0.15, up 33.38% from the prior year.
- Interest Coverage Ratio rose to 1.02 in Q1 2026, from 3.92 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.05 in Q4 2024 to a low of 369.27 in Q2 2024.
- A 5-year average of 52.66 and a median of 3.08 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio surged 78.09% — and 2024, when it plunged 16419.07%.
- Tracing NERV's Interest Coverage Ratio over 5 years: stood at 0.06 in 2022, then plunged by 31.6% to 0.07 in 2023, then jumped by 36.41% to 0.05 in 2024, then slumped by 8231.74% to 3.92 in 2025, then soared by 73.88% to 1.02 in 2026.
- The last three Interest Coverage Ratio figures came in at 1.02 (Q1 2026), 3.92 (Q4 2025), and 0.05 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | - |